• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Helix Acquisition Corp. (Amendment)

    11/15/21 4:34:29 PM ET
    $HLXA
    Business Services
    Finance
    Get the next $HLXA alert in real time by email
    SC 13G/A 1 tm2132844d5_sc13ga.htm SCHEDULE13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    ______________

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    HELIX ACQUISITION CORP.

    (Name of Issuer)

     

    Class A Ordinary Share, par value $0.0001 per share

    (Title of Class of Securities)

     

    G4444C102

    (CUSIP Number)

     

    ___________November 15, 2021__________

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. G4444C102

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Management, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0 

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    6

    SHARED VOTING POWER

     

    0

    REPORTING

    PERSON

    WITH:

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IA, PN

     

     

     

     

     

    CUSIP No. G4444C102

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Peter Kolchinsky

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0 

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    6

    SHARED VOTING POWER

     

    0

    REPORTING

    PERSON

    WITH:

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

     

     

    CUSIP No. G4444C102

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Rajeev Shah

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)       ¨

    (b)       ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

     

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0 

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    6

    SHARED VOTING POWER

     

    0

    REPORTING

    PERSON

    WITH:

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0%

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    HC, IN

     

     

     

     

     

      

    CUSIP No. G4444C102

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    RA Capital Healthcare Fund, L.P.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

    (a)      ¨

    (b)      ¨

     

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

     

     

    NUMBER OF

    5

    SOLE VOTING POWER

     

    0 

    SHARES

    BENEFICIALLY 

    OWNED BY

    EACH

    6

    SHARED VOTING POWER

     

    0

    REPORTING

    PERSON

    WITH:

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ¨

      

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0% 

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN 

     

     

     

     

     

    Item 1(a). Name of Issuer:

     

      Helix Acquisition Corp. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

      Cormorant Asset Management, LP, 200 Clarendon Street, 52nd Floor, Boston, MA 02116

     

    Item 2(a).Names of Persons Filing:

     

      The names of the persons filing this report (collectively, the “Reporting Persons”) are: 
      RA Capital Management, L.P. (“RA Capital”) 
      Peter Kolchinsky 
      Rajeev Shah 
      RA Capital Healthcare Fund, L.P. (the “Fund”)

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

      The address of the principal business office of each of the Reporting Persons is:

     

      c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

     

    Item 2(c).Citizenship:

     

      RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

     

    Item 2(d).Title of Class of Securities:

     

      Class A Ordinary Share, par value $0.0001 per share (“Class A Ordinary Shares”)

     

    Item 2(e) CUSIP Number:

     

      G4444C102

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      

      (e) RA Capital Management, L.P. is a registered investment adviser and is filing this statement in accordance with §240.13d-1(b)(1)(ii)(E);

     

      (g) Peter Kolchinsky and Rajeev Shah are control persons and are filing this statement in accordance with §240.13d-1(b)(1)(ii)(G).

     

    Item 4.Ownership.

     

      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

     

     

     

    (a)

    Amount Beneficially Owned:

    See the response(s) to Item 9 on the attached cover page(s). 

     

    (b)

    Percent of Class:

    See the response(s) to Item 11 on the attached cover page(s).

       
    (c)

    Number of shares as to which such person has: 

       
      (i)

    sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

         
      (ii)

    shared power to vote or to direct the vote

    See the response(s) to Item 6 on the attached cover page(s).

         
      (iii)

    sole power to dispose or to direct the disposition of

    See the response(s) to Item 7 on the attached cover page(s).

         
      (iv)

    shared power to dispose or to direct the disposition of

    See the response(s) to Item 8 on the attached cover page(s).

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

      Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

      Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

      Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

      Not applicable.

     

    Item 10.Certification.

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 15, 2021  
         
    RA CAPITAL MANAGEMENT, L.P.  
         
    By: /s/ Peter Kolchinsky  
    Name: Peter Kolchinsky  
    Title: Authorized Signatory  
         
    PETER KOLCHINSKY  
       
    /s/ Peter Kolchinsky  
         
    RAJEEV SHAH  
       
    /s/ Rajeev Shah  
         
    RA CAPITAL HEALTHCARE FUND, L.P.  
         
    By: RA Capital Healthcare Fund GP, LLC  
    Its: General Partner  
         
    By: /s/ Peter Kolchinsky  
    Name: Peter Kolchinsky  
    Title: Manager  

     

     

     

    Get the next $HLXA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HLXA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HLXA
    SEC Filings

    See more
    • SEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)

      S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

      7/26/22 8:43:13 AM ET
      $HLXA
      Business Services
      Finance
    • SEC Form S-1/A filed by Helix Acquisition Corp. (Amendment)

      S-1/A - MoonLake Immunotherapeutics (0001821586) (Filer)

      7/15/22 5:08:30 PM ET
      $HLXA
      Business Services
      Finance
    • Helix Acquisition Corp. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits

      8-K - MoonLake Immunotherapeutics (0001821586) (Filer)

      6/17/22 4:05:44 PM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

       - Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp's trust account and a private investment in public entity (PIPE) financing - Leading institutional investors commit $115 million through a PIPE led by Cormorant Asset Management - Business combination is expected to be completed late in the fourth quarter of 2021 or early in the first quarter of 2022 - The combined company plans to advance clinical development of the tri-specific Nanobody® sonelokimab for the treatment of skin and joint diseases driven by IL-17A and IL-17F MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapi

      10/4/21 7:00:00 AM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Sturge Simon

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      5/5/22 5:51:12 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form 4 filed by Xavier Ramnik

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      5/5/22 5:49:11 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form 4 filed by Moukheibir Catherine

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      5/5/22 5:47:33 PM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Helix Acquisition Corp.

      SC 13D - MoonLake Immunotherapeutics (0001821586) (Subject)

      4/18/22 4:49:17 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Helix Acquisition Corp. (Amendment)

      SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

      2/14/22 2:35:06 PM ET
      $HLXA
      Business Services
      Finance
    • SEC Form SC 13G/A filed by Helix Acquisition Corp. (Amendment)

      SC 13G/A - Helix Acquisition Corp (0001821586) (Subject)

      2/14/22 6:12:44 AM ET
      $HLXA
      Business Services
      Finance

    $HLXA
    Leadership Updates

    Live Leadership Updates

    See more
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services